Chemically-altered synthetic high-profit derivatives of vitamin D (eldecalcitol) should not be called "vitamin D" in research, practice, or public discussion
Medical journals feed the drug-dependency machine by publishing bogus nonsensical studies that make nutrition look evil and drugs look holy
The virtue-signaling British Medical Journal (BMJ) published the study “Effect of active vitamin D treatment on development of type 2 diabetes” without informing readers that vitamin D was not used in the study.
The authors1 inappropriately described the compound “eldecalcitol” as “active vitamin D” which is a lie because eldecalcitol is not vitamin D and does not behave in the body as does vitamin D. Clear evidence of its failure is found in the article wherein the authors note that giving eldecalcitol fails to raise 25-oh-vitaminD levels.
As I have said before, 25-oh-vitaminD is the active form of vitamin D, accounting for 80% of the biological activity of vitamin D in the body.
Because vitamin D is inexpensive a solves a wide range of health problems, drug companies are trying to make synthetic patentable and high-profit forms of vitamin D. They will ignore and attack vitamin D until they can make a synthetic modification of it that they can then sell as a high-profit prescription drug—this is exactly what they have already done with fish oil.*
Eldecalcitol, which was developed by Chugai Pharmaceutical Co., Ltd. as a treatment with the potential of becoming the drug of first choice for osteoporosis, is a new derivative of active vitamin D3 (1,25(OH) 2D3) with a hydroxypropyloxy group introduced at the 2β position.2
For the drug-medical complex, vitamin D is the enemy because it is the solution for millions of people suffering from pain, depression, anxiety, infections and autoimmunity.
See my articles and videos on vitamin D compiled at the following link:
* See my posts on the 2018-2019 fish oil fiasco:
Effect of active vitamin D treatment on development of type 2 diabetes: DPVD randomised controlled trial in Japanese population BMJ 2022; 377 doi: https://doi.org/10.1136/bmj-2021-066222 (Published 25 May 2022) Cite this as: BMJ 2022;377:e066222
Eldecalcitol, which was developed by Chugai Pharmaceutical Co., Ltd. as a treatment with the potential of becoming the drug of first choice for osteoporosis, is a new derivative of active vitamin D3 (1,25(OH) 2D3) with a hydroxypropyloxy group introduced at the 2β position. https://keio.pure.elsevier.com/en/publications/overview-of-the-clinical-pharmacokinetics-of-eldecalcitol-a-new-a